KR20220061249A - 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법 - Google Patents

수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법 Download PDF

Info

Publication number
KR20220061249A
KR20220061249A KR1020227013566A KR20227013566A KR20220061249A KR 20220061249 A KR20220061249 A KR 20220061249A KR 1020227013566 A KR1020227013566 A KR 1020227013566A KR 20227013566 A KR20227013566 A KR 20227013566A KR 20220061249 A KR20220061249 A KR 20220061249A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
therapeutic compound
moisture
granules
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227013566A
Other languages
English (en)
Korean (ko)
Inventor
제임스 코왈스키
오스카 칼브
아부 티. 엠. 세라주딘
야틴드라 조시
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35447883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220061249(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20220061249A publication Critical patent/KR20220061249A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227013566A 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법 Withdrawn KR20220061249A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US60532704P 2004-08-27 2004-08-27
US60/605,327 2004-08-27
US61682804P 2004-10-07 2004-10-07
US60/616,828 2004-10-07
KR1020207019819A KR20200087870A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
PCT/EP2005/009252 WO2006021455A1 (en) 2004-08-27 2005-08-26 Fast release composition including melt granules of a moisture sensitive drug and process for manufacturing thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207019819A Division KR20200087870A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법

Publications (1)

Publication Number Publication Date
KR20220061249A true KR20220061249A (ko) 2022-05-12

Family

ID=35447883

Family Applications (8)

Application Number Title Priority Date Filing Date
KR1020227013566A Withdrawn KR20220061249A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020197001094A Ceased KR20190006612A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020077004461A Ceased KR20070049646A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물및 그의 제조방법
KR1020167002363A Withdrawn KR20160017123A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020137009959A Expired - Fee Related KR101613775B1 (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020167032323A Withdrawn KR20160136465A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020177024422A Ceased KR20170103039A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020207019819A Ceased KR20200087870A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법

Family Applications After (7)

Application Number Title Priority Date Filing Date
KR1020197001094A Ceased KR20190006612A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020077004461A Ceased KR20070049646A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물및 그의 제조방법
KR1020167002363A Withdrawn KR20160017123A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020137009959A Expired - Fee Related KR101613775B1 (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020167032323A Withdrawn KR20160136465A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020177024422A Ceased KR20170103039A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
KR1020207019819A Ceased KR20200087870A (ko) 2004-08-27 2005-08-26 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법

Country Status (21)

Country Link
US (1) US20080050443A1 (https=)
EP (2) EP3087975A1 (https=)
JP (1) JP5147399B2 (https=)
KR (8) KR20220061249A (https=)
CN (1) CN101010068B (https=)
AR (1) AR050615A1 (https=)
AU (1) AU2005276583B2 (https=)
BR (1) BRPI0514682B8 (https=)
CA (1) CA2575499A1 (https=)
DK (1) DK1786401T3 (https=)
ES (1) ES2647671T3 (https=)
HU (1) HUE034653T2 (https=)
MX (1) MX2007002253A (https=)
MY (1) MY144297A (https=)
PE (1) PE20060652A1 (https=)
PL (1) PL1786401T3 (https=)
PT (1) PT1786401T (https=)
RU (1) RU2383332C2 (https=)
SI (1) SI1786401T1 (https=)
TW (1) TWI402082B (https=)
WO (1) WO2006021455A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2766487C2 (ru) 2004-01-20 2022-03-15 Новартис Аг Композиция и способ прямого прессования
AU2005210285B2 (en) 2004-02-05 2008-01-24 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
AR050615A1 (es) 2004-08-27 2006-11-08 Novartis Ag Composiciones farmaceuticas para la administracion oral
EP1995237A4 (en) 2006-03-08 2011-07-06 Kyorin Seiyaku Kk PROCESS FOR PREPARING AN AMINOACETYLPYRROLIDINCARBONITRILE DERIVATIVE AND PRODUCTION PRODUCT THEREOF
WO2007128801A1 (en) * 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
WO2008114857A1 (ja) 2007-03-22 2008-09-25 Kyorin Pharmaceutical Co., Ltd. アミノアセチルピロリジンカルボニトリル誘導体の製造方法
DE102008020701A1 (de) * 2008-04-24 2009-10-29 Bayer Technology Services Gmbh Formulierung mit reduzierter Hygroskopizität
WO2010016584A1 (ja) * 2008-08-07 2010-02-11 杏林製薬株式会社 ビシクロ[２．２．２]オクチルアミン誘導体の製造方法
KR20110044780A (ko) * 2008-08-14 2011-04-29 교린 세이야꾸 가부시키 가이샤 안정화된 의약 조성물
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
CN102438617A (zh) 2009-03-27 2012-05-02 杏林制药株式会社 含有碱性添加剂的基质型缓释制剂
JP2011057586A (ja) * 2009-09-08 2011-03-24 Kyorin Pharmaceutical Co Ltd ｐＨ非依存性マトリックス型徐放性製剤
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
US8989577B2 (en) 2012-06-21 2015-03-24 Qualcomm Incorporated Methods and systems for implementing time-division duplexing in the physical layer
US9071358B2 (en) 2012-06-21 2015-06-30 Qualcomm Incrorporated Repeater fiber-coax units
US9363017B2 (en) 2012-07-06 2016-06-07 Qualcomm Incorporated Methods and systems of specifying coaxial resource allocation across a MAC/PHY interface
JP6283316B2 (ja) * 2012-10-26 2018-02-21 株式会社三和化学研究所 アナグリプチン含有固形製剤
US10369108B2 (en) * 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
CN104274408A (zh) * 2013-07-10 2015-01-14 北京科信必成医药科技发展有限公司 一种熔融包衣的速释药物微粒及其制备方法
US20150366813A1 (en) * 2014-06-20 2015-12-24 Banner Life Sciences Llc Liquid-filled immediate release soft gelatin capsules
PL3512505T3 (pl) 2016-09-16 2023-08-07 Galenicum Health S.L.U. Farmaceutyczne kompozycje wildagliptyny
CN117695279A (zh) * 2023-11-28 2024-03-15 九华华源药业(桂林)有限公司 氯雷他定组合物及氯雷他定药物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109770A0 (en) 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
WO1995005808A1 (en) * 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
PT654263E (pt) 1993-11-23 2002-06-28 Euro Celtique Sa Metodo para a preparacao de uma composicao de libertyacao prolongada
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US20020142037A1 (en) 1996-10-01 2002-10-03 Nabil Farah Process for the manufacture of a pharmaceutical composition with modified release of active principle comprising a matrix
WO1998018763A1 (en) 1996-10-25 1998-05-07 Tanabe Seiyaku Co., Ltd. Tetrahydroisoquinoline derivatives
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
CA2302275C (en) * 1997-09-19 2009-12-08 Shire Laboratories, Inc. Solid solution beadlet
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6107317A (en) 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
SK10802003A3 (sk) 2001-02-02 2004-05-04 Takeda Chemical Industries, Ltd. Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
AU2003262059A1 (en) * 2002-09-11 2004-04-30 Takeda Pharmaceutical Company Limited Sustained release preparation
CA2502269C (en) 2002-10-18 2009-12-22 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
ATE469645T1 (de) 2002-10-23 2010-06-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
AR050615A1 (es) 2004-08-27 2006-11-08 Novartis Ag Composiciones farmaceuticas para la administracion oral

Also Published As

Publication number Publication date
CN101010068B (zh) 2013-05-22
RU2383332C2 (ru) 2010-03-10
RU2007110953A (ru) 2008-10-10
KR20130043697A (ko) 2013-04-30
WO2006021455A1 (en) 2006-03-02
MY144297A (en) 2011-08-29
KR20200087870A (ko) 2020-07-21
BRPI0514682A (pt) 2008-06-17
KR101613775B1 (ko) 2016-04-19
KR20070049646A (ko) 2007-05-11
TWI402082B (zh) 2013-07-21
PE20060652A1 (es) 2006-08-11
BRPI0514682B8 (pt) 2021-05-25
KR20170103039A (ko) 2017-09-12
KR20190006612A (ko) 2019-01-18
EP1786401A1 (en) 2007-05-23
US20080050443A1 (en) 2008-02-28
JP5147399B2 (ja) 2013-02-20
CN101010068A (zh) 2007-08-01
JP2008510764A (ja) 2008-04-10
MX2007002253A (es) 2007-04-20
SI1786401T1 (sl) 2017-12-29
BRPI0514682B1 (pt) 2019-06-04
DK1786401T3 (da) 2017-11-27
KR20160017123A (ko) 2016-02-15
AR050615A1 (es) 2006-11-08
CA2575499A1 (en) 2006-03-02
EP3087975A1 (en) 2016-11-02
EP1786401B1 (en) 2017-08-16
ES2647671T3 (es) 2017-12-26
HUE034653T2 (hu) 2018-02-28
PL1786401T3 (pl) 2018-01-31
PT1786401T (pt) 2017-11-22
TW200613005A (en) 2006-05-01
KR20160136465A (ko) 2016-11-29
AU2005276583A1 (en) 2006-03-02
AU2005276583B2 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
KR101613775B1 (ko) 수분 민감성 약물의 용융 과립을 포함하는 속방출성 조성물 및 그의 제조방법
EP1441713B1 (en) Modified release tamsulosin tablets
JP5816091B2 (ja) ナトリウムオキシベートの即時放出投薬形態
CA2688721A1 (en) Stable pharmaceutical formulation for a dpp-iv inhibitor
EP4025192B1 (en) Process for producing a tablet comprising glp-1 peptides
CA2801020A1 (en) A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
RS53087B (sr) Čvrste farmaceutske kompozicije stalnog sastava koje sadrže irbesartan i amlodipin, njihovo dobijanje i terapijska primena
EA030466B1 (ru) Фармацевтическая композиция, обладающая улучшенной стабильностью
EP2515880A2 (en) Novel pharmaceutical compositions of ranolazine
JP2015091830A (ja) 有機化合物のガレヌス製剤
HK1227314A1 (en) Treatment with vildagliptin
TR201802243T4 (tr) Vildagliptin ve gliklazid kombinasyon kompozisyonu.
WO2005092319A1 (en) Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
WO2009105049A1 (en) Oral tablet compositions containing nateglinide and surfactan ph adjusting agent

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220422

Application number text: 1020207019819

Filing date: 20200708

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid